Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

6(75.0%)

Early Phase 1

1(12.5%)

Phase 1

1(12.5%)

8Total

N/A(6)

Early Phase 1(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07161830Not ApplicableRecruiting

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

Role: lead

NCT05921292Early Phase 1Completed

Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

Role: lead

NCT05417425Phase 1Completed

Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers

Role: lead

NCT05291169Not ApplicableCompleted

Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers

Role: lead

NCT04510675Not ApplicableCompleted

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

Role: lead

NCT04512274Not ApplicableCompleted

Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin

Role: lead

NCT04198441Not ApplicableUnknown

The Omeza Protocol for Chronic Ulcers

Role: lead

NCT04510376Not ApplicableCompleted

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

Role: lead

All 8 trials loaded